ArticleEBioMedicine2016
Urinary Metabolomics Identifies a Molecular Correlate of Interstitial Cystitis/Bladder Pain Syndrome in a Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network Cohort.
Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- The Metabolomics of Chronic Pain Conditions: A Systematic Review.Biological research for nursing · 2020Pooled it
- Biomarkers in the diagnosis and symptom assessment of patients with bladder pain syndrome: a systematic review.International urogynecology journal · 2019Pooled it
- Microbiome and chronic pelvic pain in women: a mini-review.Human reproduction (Oxford, England) · 2026Review
- Triamcinolone acetonide nanoparticles ameliorate interstitial cystitis and anxiety/depression by targeting the bladder-metabolic-brain axis.Materials today. Bio · 2026Article
- Integrating biomarker clustering for improved diagnosis of interstitial cystitis/bladder pain syndrome: a review.International urology and nephrology · 2025Review
- Development of a metabolome-based respiratory infection prognostic during COVID-19 arrival.mBio · 2025Article
- Lipid Alterations in Chronic Nonspecific Low Back Pain in the Chinese Population: A Metabolomic and Lipidomic Study.Bioengineering (Basel, Switzerland) · 2024Article
- Presurgical blood metabolites and risk of postsurgical pelvic pain in young patients with endometriosis.Fertility and sterility · 2022Observational
- Peptidomics analysis reveals changes in small urinary peptides in patients with interstitial cystitis/bladder pain syndrome.Scientific reports · 2022Article
- In-depth characterisation of the urine metabolome in cats with and without urinary tract diseases.Metabolomics : Official journal of the Metabolomic Society · 2022Article
- Metabolomics in chronic pain research.European journal of pain (London, England) · 2021Review
- Combined Signature of the Urinary Microbiome and Metabolome in Patients With Interstitial Cystitis.Frontiers in cellular and infection microbiology · 2021Article
- Metabolomic and lipidomic approaches to identify biomarkers for bladder cancer and interstitial cystitis (Review).Molecular medicine reports · 2020Review
- Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities.Nature reviews. Neurology · 2020Review
- Bladder Pain Syndrome and Interstitial Cystitis Beyond Horizon: Reports from the Global Interstitial Cystitis/Bladder Pain Society (GIBS) Meeting 2019 Mumbai - India.Anesthesiology and pain medicine · 2020Article
- Metabolomics in Central Sensitivity Syndromes.Metabolites · 2020Review
- Advances in urinary biomarker discovery in urological research.Investigative and clinical urology · 2020Review
- Leveraging Human Microbiome Features to Diagnose and Stratify Children with Irritable Bowel Syndrome.The Journal of molecular diagnostics : JMD · 2019Article
- Urologic chronic pelvic pain syndrome: insights from the MAPP Research Network.Nature reviews. Urology · 2019Review
- Current best practice management of interstitial cystitis/bladder pain syndrome.Therapeutic advances in urology · 2018Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
Abstract
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a poorly understood syndrome affecting up to 6.5% of adult women in the U.S. The lack of broadly accepted objective laboratory markers for this condition hampers efforts to diagnose and treat this condition. To identify biochemical markers for IC/BPS, we applied mass spectrometry-based global metabolite profiling to urine specimens from a cohort of female IC/BPS subjects from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. These analyses identified multiple metabolites capable of discriminating IC/BPS and control subjects. Of these candidate markers, etiocholan-3α-ol-17-one sulfate (Etio-S), a sulfoconjugated 5-β reduced isomer of testosterone, distinguished female IC/BPS and control subjects with a sensitivity and specificity >90%. Among IC/BPS subjects, urinary Etio-S levels are correlated with elevated symptom scores (symptoms, pelvic pain, and number of painful body sites) and could resolve high- from low-symptom IC/BPS subgroups. Etio-S-associated biochemical changes persisted through 3-6months of longitudinal follow up. These results raise the possibility that an underlying biochemical abnormality contributes to symptoms in patients with severe IC/BPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.